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Introduction: Non-invasive diffuse optical tomography (DOT) and diffuse correlation spectroscopy (DCS) can detect
and characterize breast cancer and predict tumor responses to neoadjuvant chemotherapy, even in patients with
radiographically dense breasts. However, the relationship between measured optical parameters and pathological
biomarker information needs to be further studied to connect information from optics to traditional clinical cancer
biology. Thus we investigate how optically measured physiological parameters in malignant tumors such as oxy-,
deoxy-hemoglobin concentration, tissue blood oxygenation, and metabolic rate of oxygen correlate with microscopic
histopathological biomarkers from the same malignant tumors, e.g., Ki67 proliferation markers, CD34 stained vasculature
markers and nuclear morphology.
Methods: In this pilot study, we investigate correlations of macroscopic physiological parameters of malignant tumors
measured by diffuse optical technologies with microscopic histopathological biomarkers of the same tumors, i.e., the
Ki67 proliferation marker, the CD34 stained vascular properties marker, and nuclear morphology.
Results: The tumor-to-normal relative ratio of Ki67-positive nuclei is positively correlated with DOT-measured relative
tissue blood oxygen saturation (R = 0.89, p-value: 0.001), and lower tumor-to-normal deoxy-hemoglobin concentration
is associated with higher expression level of Ki67 nuclei (p-value: 0.01). In a subset of the Ki67-negative group (defined
by the 15 % threshold), an inverse correlation between Ki67 expression level and mammary metabolic rate of oxygen
was observed (R = −0.95, p-value: 0.014). Further, CD34 stained mean-vessel-area in tumor is positively correlated with
tumor-to-normal total-hemoglobin and oxy-hemoglobin concentration. Finally, we find that cell nuclei tend to have
more elongated shapes in less oxygenated DOT-measured environments.
Conclusions: Collectively, the pilot data are consistent with the notion that increased blood is supplied to breast
cancers, and it also suggests that less conversion of oxy- to deoxy-hemoglobin occurs in more proliferative cancers.
Overall, the observations corroborate expectations that macroscopic measurements of breast cancer physiology using
DOT and DCS can reveal microscopic pathological properties of breast cancer and hold potential to complement
pathological biomarker information.* Correspondence: sochung@sas.upenn.edu
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Diffuse optical imaging and spectroscopy measure deep
tissue physiology in vivo using low-power non-ionizing
light, and in recent years, cancer research with diffuse
optics has become more quantitative [1–3]. Several fea-
tures of diffuse optics make the technology appealing for
use in patients with breast cancer, including technical
simplicity, portability, soft compression of the breast,
non-invasiveness and the cost. Furthermore, the tech-
nology has been demonstrated to detect/characterize
breast tissue properties regardless of patient age and
breast radiographic density [4–8], and it can be used to
monitor patient responses to therapy continuously at the
bedside [9–14].
The primary endogenous physiological information de-
rived from diffuse optical measurements is oxyhemoglobin,
deoxyhemoglobin and total hemoglobin concentration,
tissue blood oxygenation [1, 3, 5–8, 14, 15], blood flow
[13, 16], and water and lipid concentration [1, 3, 5–8, 14, 15].
More recently, tissue temperature, the binding state of
water [7, 10, 17–19] and collagen [20, 21] are proving to
be interesting biomarkers. Several groups have reported
contrast between breast cancer, benign lesions, and normal
tissues based on these physiological parameters [6, 22–24],
and tumor responses to neoadjuvant chemotherapy (NAC)
have been monitored successfully [9, 11, 13, 14, 25–27].
Some of these responses predict complete versus non-
complete pathologically determined response among pa-
tients during the early stages of NAC [9, 28, 29] and even
before therapy [30].
In this paper we examine how macroscopic diffuse op-
tical parameters are related to microscopic pathology in-
formation that clinicians typically employ for treatment
strategy decisions. In clinical practice, tumor samples are
characterized based on microscopic analyses of immuno-
histologically stained biopsy specimens. For example, Ki67
expression level in cell nuclei is often assessed to quantify
proliferation of cancer cells [31, 32], and CD34 staining is
used for quantifying endothelial cells of micro-vessels in
order to assess angiogenesis in tumors [33]. A few studies
have compared microscopic markers to the parameters
derived from diffuse optical images [30, 34–39]. Total
hemoglobin concentration in breast cancer, for example,
has been positively correlated with vascular properties
such as micro-vessel density [37–39]. Although correla-
tions between Ki67 proliferation marker expression level
and diffuse optically measured physiological parameters
have not been reported, several positron emission tomog-
raphy (PET) studies have found correlation between Ki67
cancer proliferation level and fluorodeoxyglucose (FDG)
metabolism [40–42], but a different study reported no
correlation between Ki67 and 18F-FDG uptake, and a mar-
ginal correlation between Ki67 expression level and
tumor-to-background ratio of the uptake of the hypoxia-avid compound 18F-labeled fluoromisonidazole (18F-FMISO)
[43]. The authors of the latter paper concluded that their
observations might be due to alteration of glucose metab-
olism in cancer that prefers aerobic glycolysis, a phe-
nomenon known as the Warburg effect [44]. In the work
of Cochet et al. [41], no significant correlation was found
between standardized uptake of 18F-FDG and endothelial
markers (CD34 and CD105). Note also, tumor blood flow
indices defined by these authors correlated positively with
the expression of CD34 and CD105 and with the expres-
sion of Ki67 [41].
Our pilot study provides a more extensive exploration
of the potential connections between tissue parameters
obtained from diffuse optical tomography (DOT) and
diffuse correlation spectroscopy (DCS), and standard
histopathological biomarkers derived from the same pa-
tient tissues. In previous research we demonstrated that
the tumor-to-normal ratio of a variety of parameters in
three-dimensional (3-D) DOT images can differentiate
benign from malignant breast lesions [6]. Here we focus
on malignant tumor properties. Specifically, we investi-
gated how DOT-based physiological parameters in malig-
nant tumors, such as oxyhemoglogin, deoxyhemoglobin
concentrations, tissue blood oxygenation, and tumor-to-
normal ratio of the mammary metabolic rate of oxygen
(rMMRO2) (derived from hemoglobin concentration and
DCS blood flow data) correlate with microscopic histo-
pathological biomarkers from the same malignant tumors,
i.e., with the Ki67 proliferation marker, the CD34 stained
vasculature marker, nuclear morphology and with hormo-
nal receptor status of breast cancer.
Methods
Subjects
The University of Pennsylvania Institutional Review Board
approved our measurement protocol. Written informed
consent was obtained from each subject for the diffuse op-
tical measurements and for publishing the data. For this
retrospective study, written informed consent was not
required for retrieval of specimens routinely stored in the
tissue bank. From 37 subjects with cancer analyzed with
DOT in our previous publications [6, 16], corresponding
pathology slides for 21 subjects were available for add-
itional staining of Ki67 and CD34. Specimens from the
remaining subjects were not stored in the tissue bank
from which we retrieved the tissues. Although some sam-
ples were not available for additional staining, information
on 11 of these subjects was acquired from standard-of-
care pathology reports for the correlation study with
tumor grade and hormonal/genetic subtypes. Thus, a total
32 subjects with infiltrating ductal carcinoma were studied
in this paper.
In the 21 subjects used for Ki67, CD34 and nuclear
morphology analysis, DOT measurements were performed
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jects (DOT measurements were made 5 days before the
biopsy on average, i.e., 43 % of the sample); (2) prior to
core biopsy in 2 subjects (DOT measurements were made
8 days prior to excision of the entire tumor on average,
i.e., 9 %), and (3) ≥2 weeks after the biopsy and prior to ex-
cision of the entire tumor in 10 subjects (DOT measure-
ments were made 18 days prior to excision of the entire
tumor on average, i.e., 48 %).
For the full sample of 32 subjects, DOT measurements
were performed (1) prior to any biopsy in 11 subjects
(DOT measurements were made 5 days before the bi-
opsy on average, 34 %); (2) prior to core biopsy in 6 sub-
jects (DOT measurements were made 18 days prior to
excision of the entire tumor, 19 %), and (3) ≥2 weeks
after the biopsy and prior to excision of the entire tumor
in 15 subjects (DOT measurements were made 22 days
prior to excision of the entire tumor on average, 47 %).
We did not observe any biopsy-induced bruises (black
or blue) in any subjects, i.e., the patients' biopsy sites
healed sufficiently that no visible signs were apparent. In
addition, by comparing optical data obtained before ver-
sus after biopsy, Choe et al. [6] explicitly tested whether
such biopsies affect tumor optical contrast, and no sig-
nificant differences were found in that investigation.
Therefore, we expect that the DOT patient measure-
ments in the present work were not influenced by the
biopsies. Different numbers of subjects were studied for
each biomarker for various reasons, as described below
(also see Additional file 1: Table S1).
Ki67
Samples from 18 out of the 21 subjects initially chosen
for Ki67 evaluation were used; two slides lacked suffi-
cient cancer tissue and one slide had uneven thickness
(which caused out-of-focus microscopic imaging for this
computer-assisted analysis). For the calculation of the
tumor-to-normal ratio of Ki67 (rKi67), we only used
samples from subjects with Ki67 expression in normal
tissues, which corresponded to 9 out of the 18 subjects.
These 9 cases were found to be pre-menopausal pa-
tients. All 18 subjects were used for the cancer-only ana-
lysis; Ki67 expression in confirmed cancer tissues from
all patients was available for this analysis. (Note, this
number is the numerator of the tumor-to-normal ratio
(rKi67) for the patients who had both tumor and normal
tissue Ki67 expression.) Samples were available for six
subjects only for the comparison study between rMMRO2
(see Diffuse correlation spectroscopy (DCS)) and relative
mammary metabolic rate of oxygen (rMMRO2)) and Ki67
expression level, because blood flow data are required to
calculate rMMRO2, and blood flow was measured by dif-
fuse correlation spectroscopy in only six of the subjects in-
cluded in this retrospective analysis. Among the six subjects,five had low Ki67 values and belonged to the Ki67-negative
group; samples from these subjects were investigated for cor-
relation with rMMRO2. Of these six, only two subjects
had Ki67 expression in normal tissues and were therefore
available for rMMRO2 versus rKi67 analysis.
CD34
Only the vascular structures of cancer tissues were avail-
able for study, because normal vessels were rarely ob-
served adjacent to the biopsied cancer tissues. Generally,
normal vessels appear far outside of the entire tumor
structure, and therefore normal vessels were seldom ob-
served in the small specimens. Of the 21 subjects, 19
were available for this analysis, because one specimen
slide had uneven thickness and did not have sufficient
cancer tissue for analysis.
Nuclear compactness
Samples from all 21 subjects were available for the nu-
clear compactness analysis.
Other analyses
In addition to the 21 subjects described above, we ana-
lyzed samples from an additional 11 subjects for whom
DOT images and clinical pathology reports were avail-
able. Unfortunately, there were no tissue samples from
these subjects for the additional staining described
above. These additional subjects were included in some
of our analyses to investigate the relationship between
DOT physiological parameters, hormonal and genetic
features, and breast cancer tumor grade. Among the
total of 32 subjects, modified Bloom-Richardson scores
were available for 29 subjects, and cancer hormonal
status was reported for 31 subjects.
Diffuse optical tomography (DOT)
Details of the DOT system, measurement procedure and
reconstruction algorithm are described in Choe et al. [6].
Briefly, the instrument employed the parallel-plate geom-
etry for source and detector planes; a breast box was uti-
lized wherein breasts were positioned while the subject
was lying in a prone position. The breasts were com-
pressed mildly to hold them in a stable position. An
outline of the breast surface was obtained by a 16-bit
charge-coupled-device (CCD) camera. An Intralipid/ink
(Baxter, Deerfield, IL) solution with optical properties
similar to breast tissue filled the box to form a background
diffuse medium and thereby reduce dynamic-range re-
quirements. Four lasers at 690, 750, 786 and 830 nm were
modulated at 70 MHz, and two lasers at 650 and 905 nm
were used in continuous-wave (CW) mode. Laser light was
delivered to 45 source locations using optical switches
shown as red dots in Fig. 1. The source plane also had nine
fibers embedded within it (yellow dots in Fig. 1) for
Fig. 1 Instrumental setup for the diffuse optical tomography (DOT) system, and DOT images acquired from a 53-year-old woman with a 2.2-cm
(longest dimension) invasive ductal carcinoma. Bottom left depicts a three-dimensional tumor region (red). The images of rHb, rHbO2 and rStO2 are
for relative (i.e., tumor-to-normal ratio) deoxyhemoglobin and oxyhemoglobin concentration and tissue oxygenation, respectively. Black solid line
in the images indicates the region identified as tumor. FD frequency domain, CCD charge-coupled-device camera
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These frequency-domain (FD) measurements provided
bulk optical properties that served as initial guesses for
further reconstruction. CW-domain transmission mea-
surements were made through a transparent window util-
izing the CCD camera. The 45 source locations and the
CCD camera enabled collection of a very large dataset for
reconstruction of 3-D optical images. The diffuse optical
data for the images were acquired in 8–12 minutes. Fol-
lowing the subject measurement, a phantom calibration
measurement was performed after fully filling the breast
box with the same Intralipid/ink solution and covering the
top of the box with a silicone slab to mimic the chest wall.
A brief description on the reconstruction steps for gener-
ating 3-D optical images is included in Additional file 1.
Three-dimensional images of oxyhemoglobin, deoxyhemo-
globin and total hemoglobin concentrations, tissue oxygen-
ation and reduced-scattering coefficients were obtained.
Determination of tumor boundaries in the optical
images has previously been described [6]. Briefly, an ap-
proximate location for the tumor was first selected based on
magnetic resonance imaging (MRI), x-ray mammographyand ultrasound images. In the selected area, the location
of the maximum intensity of the optical attenuation coef-
ficient at 786 nm was found (tumors have higher optical
attenuation coefficients than normal tissues), and there-
after, a 3-D region was grown using the maximum in-
tensity location as a seed with a cutoff at full-width at
half-maximum. During this process, we examined the se-
lected tumor region to determine whether the optical im-
ages provided tumor location and size consistent with
the radiological imaging methods. Tumor values for each
optically derived parameter are extracted by averaging
each parameter over this entire tumor volume. Normal
tissue values are derived by averaging overall normal tis-
sues (i.e., excluding the tumor) in the same breast. The
tumor-to-normal ratio of each parameter was thus calcu-
lated; the letter ‘r’ is added in front of the abbreviation of
each parameter to indicate a relative (tumor-to-normal)
value, for example, relative tissue oxygen saturation
(rStO2), relative total hemoglobin (rTHC), relative
oxyhemoglobin (rHbO2), relative deoxyhemoglobin
(rHb) concentrations, and relative reduced-scattering
coefficients (rμs').
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mammary metabolic rate of oxygen (rMMRO2)
DCS was used to measure a blood flow index that, in
turn, was used to calculate a tumor-to-normal ratio of
mammary metabolic rate of oxygen of a subset of sub-
jects (n = 6) who also had Ki67 analysis. The DCS mea-
surements were performed on the same day as the DOT
measurements. Details about the DCS instrument, the
mathematical model and the input parameters have been
described by Choe et al. [16]. Briefly, DCS measures a
temporal intensity autocorrelation function of the de-
tected light, and the decay rate of the autocorrelation
function indicates blood flow, for example, faster decays
correlate with faster blood flow. A tissue blood flow
index, BFI, was derived from the measured DCS tem-
poral light intensity autocorrelation functions by fitting
the data to a solution of the correlation diffusion equa-
tion in the homogeneous semi-infinite geometry [1]. The
DCS system employed a 786-nm-long coherence laser as
a light source (delivered through a multi-mode fiber), a
single-mode fiber was used to collect light and a fast-
photon-counting avalanche photodiode was used for de-
tection. A custom-built correlator board determined the
normalized temporal intensity autocorrelation functions
of the detected light.
For in vivo measurements, the tumor location in a su-
pine position was identified either by palpation or by
consulting radiology reports. Then a handheld probe
with one source and one detector fiber 2.5 cm apart was
gently placed on the breast tissue and data were col-
lected from 10–12 points (1 cm apart) aligned on a line
straddling the tumor center. The tumor and normal tis-
sue points were averaged, respectively, to obtain one
representative tumor and one normal region blood flow
index for each subject. The relative blood flow (rBF) was
calculated by taking the ratio between tumor and normal
region BFI values.
Part of the analysis of this paper employed a mammary
oxygen metabolism model that was introduced by Zhou
et al. [13]. The tumor-to-normal ratio of the (relative)
mammary metabolic rate of oxygen (rMMRO2) employed
herein was slightly modified from the version introduced
by Zhou et al. to monitor metabolic changes in breast tu-








where γ represents the percentage of blood volume con-
tained in the venous component of the vascular system
(i.e., StO2 = (1− γ)SaO2 + γ SvO2 where SaO2 and SvO2
are arterial and venous oxygen saturation, respectively
[45]), the subscript T indicates tumor and N indicatesnormal tissue, and rBF is the tumor-to-normal ratio of
BFI quantified by DCS [16]. Note, the so-defined
rMMRO2 is closely related to the cerebral metabolic rate
of oxygen extraction (CMRO2) parameter that has been
studied extensively for metabolism measurements in the
brain [1, 46–49].
Microscopic analysis of tissue specimens
Slide selection and immunohistochemical analysis
Tissue blocks that include cancer tissues were reviewed,
and blocks with the most cancer tissue were selected by a
pathologist (MDF) for microscopic analysis of cancer
properties. Immunohistochemical analysis of formalin-
fixed paraffin-embedded tissue was performed using anti-
bodies against Ki67 (Clone MIB-1; DAKO, Carpinteria,
CA M7240; 1:20 dilution) and CD34 (Clone My10; BD
Biosciences, San Jose, CA 347660; 1:80 dilution) on separ-
ate slides from the selected tissue block. Staining was done
on a Leica Bond™ instrument using the Bond Polymer Re-
fine Detection System (Leica Microsystems, Buffalo
Grove, IL AR9800). Heat-induced epitope retrieval was
required for Ki67 and this was performed for 20 mi-
nutes with ER1 solution (Leica Microsystems AR9961).
Digital analysis of the staining
The stained slides were scanned using Aperio ScanScope
(Aperio, Vista, CA, USA) with ×20 objective. In order to
account for cancer heterogeneity, multiple regions of
interest (ROI) were selected in the cancer and normal
tissue samples (i.e., 2–7 ROI depending on the available
amount of tissue and degree of heterogeneity) by SHC
under the guidance of MDF and DM using the annota-
tion tool of Aperio ImageScope, and MDF re-confirmed
the selected ROI tissue types. We noticed that a few ex-
tremely dark spots appeared randomly on the slides,
mostly clusters of the staining dye. These spots cause er-
rors in the analysis, because the algorithm selects pixels
with lower intensity than a threshold value as positive
nuclei, and the dark spots have extremely low intensity
values that can result in mistaken selection as strongly
positive nuclei; thus, those areas were excluded manually
using the annotation tool. An area-weighted average of
the multiple ROI for each subject was used in the correl-
ation study. The Ki67 and CD34 stained areas were dif-
ferentiated from the non-stained areas by setting relative
values of red-green-blue (RGB) optical densities (for de-
fining the color of the stain) and the intensity of the de-
fined color. These values were optimized by iterative
adjustments: the detection algorithm with the set values
was applied to multiple sample cases and the results
were visually examined by MDF if the assigned color on
the nuclei matched the actual features of the nuclei
(Fig. 2). For Ki67 detection, the Ki67-expressing nuclei
percent of the total number of nuclei in an ROI was
Fig. 2 a Ki67-expresseing nuclei were stained by MIB-1 and appear as brown spots. Abnormal extreme dark spots caused errors in automated
analyses and were excluded manually (see blue loops). b Dark blue regions designate cells in which the nuclei did not express Ki67, and yellow
and orange regions designate cells with Ki67-expressing nuclei (note, orange signifies more intense expression). c CD34-stained vessels appear
brown. d Detected vessels were highlighted in neon green using the Aperio algorithm. e The raw image was segmented into cancer (pink) versus
non-cancerous (green) areas as shown in f. g Individual cells were detected as neon green loops. Based on nuclear shape, the compactness of the
nuclei was calculated using inForm 1.0.2 (Perkin Elmer)
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nuclear image analysis algorithm (version 10.2). We
counted 3278 nuclei per subject (on average) with a range
of 270 to 4114 in the 15 subjects (Fig. 2a, b). Then, the
tumor-to-normal ratio of Ki67-expressing nuclei was cal-
culated to derive relative Ki67 values (i.e., rKi67). For this
analysis, after subjects were selected and slides obtained,
only normal glandular tissues with Ki67 expression
(within each slide) were used.
For CD34-stained vessel properties, the Aperio micro-
vessel analysis algorithm was used. An average of 118
vessels per ROI were detected (n = 19) and used for thequantification of micro-vessel density (number of vessels
per unit area (μm2)), mean vessel and vascular area and
the ratio of stained area to ROI area. Note, the mean
vessel area includes the lumen in addition to the endo-
thelial cells that form the vascular structure. To calculate
the mean vessel/vascular area for each ROI, only vessels
with a closed cross-section were automatically detected
in the ROI first, then a mean value of the vessel/vascular
area was calculated for each ROI (Fig. 2c, d).
For the nuclei morphology analysis, binary segmenta-
tion (cancer versus non-cancer) was used instead of the
ROI selection. The digitized slides were converted to a
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Elmer). Then, using inForm 1.0.2 image analysis soft-
ware (Perkin Elmer), tumor and normal tissues were seg-
mented by the training algorithm, and the nuclear
shapes were detected and used for the calculation of the
nuclear compactness (Fig. 2e, f, g). Nuclear compactness
is calculated using the following equation:
Compactness ¼ 4π  Area=Perimeter2:
Statistical analysis
We used Pearson’s correlation coefficient (corr. coef.) to
assess the linear association between the mean of the
DOT physiological parameters and the microscopically
assessed histopathological biomarkers. We generally re-
port on possible linear relationships between the DOT
physiological parameters and several biomarkers. We
also used Spearman’s correlation coefficient to further
explore the possibility of a monotonic, but non-linear re-
lationship. The Wilcoxon ranked sum test was used to
ascertain differences in DOT parameters in Ki67-
positive and Ki67-negative groups (those defined by the
15 % cutoff threshold). The type I error rate was 0.05,
and corrections were not made for multiple comparisons
in this exploratory study.
Results
Association of DOT parameters with Ki67 cancer
proliferation
The percent range of the Ki67-nuclei used for determin-
ation of tumor-to-normal ratio of Ki67 (i.e., rKi67) varied
from 0.05−23.45 % in cancer tissues (n = 9), and from 0.19
−7.41 % in normal tissues (n = 9) (see Additional file 1:
Table S2). More subjects were included for the DOT ver-
sus cancer-only Ki67-expression comparison study,Fig. 3 Correlation between a relative tissue oxygen saturation (rStO2) and
(n = 9). Dotted lines indicate 95 % confidence interval for the mean of the
the more proliferative cancer tissuesand the Ki67 range for this latter investigation was 0.05
−27.77 % in cancer tissues (n = 18). Among the DOT pa-
rameters, rStO2 and rHbO2 were linearly correlated with
rKi67 as shown in Fig. 3 and Table 1 (Pearson correlation
of 0.89, p-value 0.001 for rStO2, and Pearson correlation
of 0.68, p-value 0.044 for rHbO2). Also, for cancer-only
Ki67, rHb was inversely correlated with cancer Ki67 per-
cent (Spearman correlation of −0.62, p-value 0.007; see
Additional file 1: Table S3 for all correlation values be-
tween DOT physiological parameters and cancer Ki67
percent). The range of Ki67 values and those of other mo-
lecular biomarkers used in the remainder of the correl-
ation studies are tabulated in Additional file 1: Table S4.
Clinically, Ki67 expression is used as a biomarker for
cancer proliferation. Tissue is termed Ki67-positive (or
Ki67-negative) if the fraction of nuclei expressing Ki67 is
above (or below) a specified cutoff, which is commonly
set at 15 % [50–53]. In the present study, we tested
whether DOT and DCS parameters are significantly dif-
ferent in more proliferative cancers compared to less
proliferative cancers (i.e., as determined by the 15 %
Ki67 cutoff ). In this scenario, only rHb was found to dif-
ferentiate Ki67-positive from Ki67-negative cancer, with
lower values of rHb occurring for Ki67-positive cancer
(p-value 0.01, Wilcoxon ranked sum test, Fig. 4a; see
Additional file 1: Table S5 for values of all DOT physio-
logical parameters of Ki67-positive and Ki67-negative
cancer groups). Among the available subjects, 15 were
Ki67-negative and 3 were Ki67-positive, but a p-value of
0.01 suggests the pilot result may be significant, even
with the limited sample size.
In the comparison between rMMRO2 and Ki67 expres-
sion level, not all the subjects were measured with DCS:
six subjects were available for analysis of the relationship
between rMMRO2 and cancer-Ki67, and two subjects for
analysis of the relationship between rMMRO2 and rKi67.rKi67 and b relative oxyhemoglobin concentration (rHbO2) and rKi67
linear fit. These pilot results suggest that more oxygen is present in
Table 1 Correlation between rKi67 and various relative DOT
parameters
Analysis of correlation with rKi67 % rStO2 rTHC rHbO2 rHb rμs’
Pearson’s correlation coefficient 0.89 0.55 0.68 −0.33 0.44
P-value 0.001 0.126 0.044 0.393 0.24
Spearman’s correlation coefficient 0.88 0.40 0.48 −0.43 0.35
P-value 0.003 0.291 0.194 0.250 0.359
Relative tissue oxygen saturation (rStO2) and relative oxyhemoglobin
concentration (rHbO2) were highly correlated with rKi67. Results with statistical
significance (p-value <0.05) are shown in bold (n = 9). rTHC denotes relative
total hemoglobin concentration, rHb denotes relative deoxyhemoglobin
concentration, and rμs' denotes relative reduced-scattering coefficients
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belonged to the Ki67-negative group; the Ki67 percentage
in these subjects exhibited significant inverse linear correl-
ation with rMMRO2 (Pearson correlation −0.95, p-value
0.014, Fig. 4b). One subject belonged to the Ki67-positive
group and did not follow the linear trend observed for the
Ki67-negative group in Fig. 4b (the Ki67-positive subject
is not shown). On analysis of the two subjects in whom
rKi67 was compared to rMMRO2, higher rKi67 was asso-
ciated with lower rMMRO2.
In addition, we ran predictability tests using the >15 %
threshold to define Ki67-positive cancer. In this case, we
found high negative predictive values (i.e., 100 %) for de-
tection of non-proliferative cancer with specific thresh-
olds for each of the DOT parameters. For example, if
values of rHb <1.1 are considered proliferative, then 100 %
of the negative predicted values are truly negative. How-
ever, given the small dataset (n = 18), the implications of
this predictability result should not be overestimated. The
main caveat is that only three subjects were in the Ki67-Fig. 4 a Relative deoxyhemoglobin concentration (rHb) versus Ki67 expres
cancer compared to Ki67-negative cancer (p-value 0.01, n = 3 for Ki67-posi
plots show the values for each individual subject. On each box, the central
percentiles and the whiskers extend to the most extreme data points not c
oxygen (rMMR2) and Ki67 in cancer for a subset of the Ki67-negative group (n
were available. Dotted lines indicate the 95 % confidence interval of the meanpositive group (15 subjects were in the Ki67-negative
group). Thus, it is difficult to ascertain the heterogeneity
of the Ki67-positive group. Albeit imperfect, the strong
correlation and predictability obtained from our DOT
data suggest that DOT holds potential to predict prolifera-
tive status of breast cancer non-invasively and that the
method is deserving of further exploration. This result can
also aid the planning of a future study that will require
more Ki67-positive samples.
Association between DOT parameters and CD34 stained
vascular properties
Blood vessels in cancer tissues were detected and ana-
lyzed using the CD34 antibody. Among all the vascular
properties accessible to this staining, i.e., micro-vessel
density, mean vessel/vascular area, and ratio of stained
area to analysis area, only mean vessel area (MVA) was
significantly and linearly correlated with rTHC and rHbO2
(Pearson correlation coefficient of 0.51, p-value 0.027 and
Pearson correlation of 0.48, p-value 0.038, respectively; see
Fig. 5, Table 2). However, it should be noted that rTHC,
rHbO2 and rμs' had higher ranked monotonic correlation
with MVA (Spearman correlation coefficient of 0.67,
p-value 0.002; Spearman correlation of 0.63, p-value 0.005;
and Spearman correlation coefficient of 0.52, p-value
0.024, respectively).
Association of DOT parameter with nuclear morphological
analysis
On nuclear morphology analysis there was weak positive
correlation between rHbO2 and the tumor-to-normal ra-
tio of nuclear compactness (Pearson correlation coeffi-
cient of 0.43, p-value 0.049, n = 21; see Additional file 1:sion in breast cancer tissues. Lower rHb is observed in Ki67-positive
tive and n = 15 for Ki67-negative cancer). Squares and circles in the box
bar is the median, the edges of the box mark the 25th and 75th
onsidered outliers. b Correlation between mammary metabolic rate of
= 5), for whom diffuse correlation spectroscopy flow measurements
of the linear fit
Fig. 5 Correlation between a relative total hemoglobin concentration (rTHC) and b relative oxyhemoglobin concentration (rHbO2) versus mean
vessel area (MVA, μm2) (n = 19). Dotted lines indicate the 95 % confidence interval of the mean of the linear fit. These pilot results suggest that
diffuse optical tomography is measuring an increased blood supply in the larger-diameter blood vessels of these cancer tissues
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physiological parameters and relative nuclear compact-
ness.). Additionally, rStO2 was weakly positively correlated
with cancer nuclear compactness (Spearman correlation
coefficient of 0.47, p-value 0.034; see Additional file 1:
Table S7 for values for correlation between all DOT
physiological parameters and relative nuclear compact-
ness.). When the nucleus is spherical, then the compact-
ness is unity. In our case, all of the measured compactness
values were smaller than unity.
As the tumor grade worsened (i.e., became higher), al-
though a slight trend of increasing rStO2 and decreasing
rHb was observed, it was not statistically significant (n =
29). Lastly, distinct differentiation of DOT parameters was
not observed in any of the estrogen receptor (ER)-, pro-
gesterone receptor (PR)- and human epidermal growth
factor-2 (HER2)-positive versus -negative groups (n = 31).
Differences between breast cancer subtypes
All but one of the samples used for the rKi67 correlation
analysis were luminal A subtype; the other sample was
basal-like and its rKi67 value was the median. For Ki67Table 2 Correlation between CD34-stained mean vessel areas
(MVA) and DOT parameters
Analysis of corrlelation with
MVA (μm2)
rStO2 rTHC rHbO2 rHb rμs’
Pearson’s correlation coefficient 0.26 0.51 0.48 −0.10 0.32
P-value 0.291 0.027 0.038 0.684 0.182
Spearman’s correlation coefficient 0.45 0.67 0.63 −0.22 0.52
P-value 0.057 0.002 0.005 0.362 0.024
MVA was correlated with relative total hemoglobin concentration (rTHC), relative
oxyhemoglobin concentration (rHbO2) and relative reduced-scattering coefficients
(rμs’) (n = 19). Results with statistical significance (p-value <0.05) are shown in
bold. DOT denotes diffuse optical tomography, rStO2 denotes relative tissue
oxygen saturation, and rHb denotes relative deoxyhemoglobin concentration(not rKi67) in cancer tissues, within the luminal A sub-
type (n = 12), negative correlation was observed between
Ki67 percent and rHb (Spearman correlation of −0.57)
with a trend towards statistical significance (p-value
0.059). No trend was observed within the basal-like sub-
type (n = 4). Correlation was not analyzed separately in
two subjects with HER2-positive cancer due to small
sample size.
In the CD34 comparison studies, within the basal-like
subtype group (n = 4), the Pearson correlation coeffi-
cient between MVA and rTHC was 0.96 (p-value 0.045).
Within the luminal A group (n = 12), several statistically
significant correlations were observed between MVA
and rTHC (Spearman correlation of 0.69, p-value 0.016),
rHbO2 (Spearman correlation of 0.71, p-value 0.012)
and rμs’ (Spearman correlation of 0.62, p-value 0.035).
Two subjects with HER2-positive and one with the
luminal B subtype were not included in the subtype
correlation analysis.
In the nuclear compactness comparison study, within
subjects with the basal-like subtype (n = 5), there was
evidence of positive correlation between rμs' and the nu-
clear compactness of cancer cells (Pearson correlation of
0.87) with a trend towards statistical significance
(p-value 0.057). No correlation was observed within the
luminal A subtypes (n = 13). Two subjects with
HER2-positive cancer and one with the luminal B sub-
type were not included in the subtype correlation
analysis.
In addition, among the group that included subjects
only with DOT images and subtype information (no tis-
sue slides, n = 32), we found that basal-like (n = 6) and
HER2-positive (n = 3) subtypes were significantly differ-
entiated (p-value 0.023) by rTHC values, although the
sample size was very small.
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Our study revealed that the tumor-to-normal (relative)
ratio of Ki67-positive nuclei is correlated positively with
rStO2 measured by DOT. This observation suggests that
the more proliferative cells reside in more oxygenated
environments, i.e., more oxygenated compared to sur-
rounding normal tissues. Further, the percentage of Ki67
nuclei in cancer-only tissues was inversely correlated
with DOT-measured rHb, and in a subset of subjects
with low Ki67 expression, an inverse correlation between
Ki67 expression level and rMMRO2 [13] was observed
(R = −0.95, p-value 0.014). We found that MVA correlated
positively with DOT-measured relative total hemoglobin
and oxyhemoglobin concentration; this observation sug-
gests that an increased blood supply to the tumors is due
to increased blood vessel size rather than blood vessel
density. The combination of these pilot results suggests
that more proliferative cancer cells demand less oxygen.
Finally, we observed that in less oxygenated environments,
cell nuclei tend to exhibit a more elongated shape. Overall,
the results of the pilot study corroborate expectations that
macroscopic measurements of breast cancer physiology
using DOT can reveal information about the microscopic
pathological properties of breast cancer and hold potential
to complement pathological biomarker information.
The Ki67 proliferation biomarker was chosen because
it is one of the biomarkers of choice for determination
of cancer severity [32, 54]. Baseline measurements of
Ki67 have correctly predicted patient prognosis [32, 55, 56],
and high levels of Ki67 predict better responses to chemo-
therapy [31, 57, 58]. The percentage ranges of the Ki67-
nuclei of our tissue samples are consistent with reported
values in the literature, including those obtained from au-
tomated evaluation methods [59, 60]. Specifically, in two
studies, more than 72 % of 379 patients [59] and 50 % [61]
of 3658 patients had cancer with <15 % Ki67 expression,
and in a study by Konsti et al., the mean Ki67 expression
level in 1334 subjects was 8.8 % [60]. By contrast, Ki67 ex-
pression level in normal breast tissues was found to be less
than 3 % in several studies [32, 62–64]. We observed that
rKi67 correlated positively with rStO2 and rHbO2. Our
finding of correlation between rStO2 and rKi67 is sup-
ported by the observations of Ueda et al. [30] who mea-
sured higher tissue oxygenation in subjects with complete
pathological response (i.e., compared to those with incom-
plete pathological response) prior to neoadjuvant chemo-
therapy. In our study, patients with higher levels of tissue
oxygenation exhibited a high level of Ki67, and the com-
bination of all reports supports the well-known finding
that a high Ki67 level predicts better response to neoadju-
vant chemotherapy [31, 57, 58]. Ki67 is known to be cor-
related with apoptosis [32, 65, 66]. One of our previous
works showed simultaneous increase of tissue oxygenation
and temperature caused by an uncoupled apoptotic stateat the beginning of neoadjuvant chemotherapy in a subject
who was found to have complete pathological response
[19]. The strong correlation between Ki67 and tissue oxy-
genation found in this current work combined with the
previous result supports the correlation between Ki67 and
apoptosis in breast cancer.
We also found that rHb was inversely correlated with
cancer-only Ki67, and that rHb was lower in Ki67-positive
cancer compared to Ki67-negative cancer (using the 15 %
cutoff, note this cutoff can vary from 10−20 % in different
clinics). It is noteworthy that in the tumors with rHb
smaller than unity (i.e., less deoxyhemoglobin in the
tumor than surrounding normal tissues), the rStO2 was
larger than unity (higher tissue oxygenation in the tumor
compared to normal tissues): this finding suggests that in
more proliferative tumors, oxygenated blood is supplied
to the tumor but the excess oxygen is not fully used.
Importantly, we took an additional step to further inves-
tigate the relationship between proliferation and oxygen
metabolism. Specifically, we calculated the tumor-to-
normal rMMRO2 in a subset of the data; only a small
number of subjects among the population were studied
in this retrospective analysis because only a small num-
ber were measured with DCS, which provides the relative
blood flow (rBF) data needed to calculate rMMRO2. In
the tumors with very low Ki67 expression, there was in-
verse correlation between oxygen metabolism and Ki67
level. In total, the full set of Ki67/DOT-parameter com-
parison studies suggest that higher tissue oxygenation
tends to arise in cancers with higher expression of Ki67,
lower deoxyhemoglobin concentration is often present in
more proliferative cancers, and tumors with rHb <1 have
rStO2 >1. Although more blood is supplied to the cancer
compared to normal tissue (i.e., all subjects had rTHC
>1), the level of oxygenated hemoglobin in the tumor re-
mains high, and less oxygen is utilized for cancer metab-
olism (yielding a lower tumor rHb).
These preliminary conclusions about the relationship
between proliferation and oxygen metabolism in breast
cancer can be explained by the Warburg effect [44], which
accounts for the fact that some cancer cells go through
glycolysis to increase biomass without using oxygen, des-
pite sufficient oxygen in the tissue environment [67, 68].
While these findings are interesting, we note that our
model for rMMRO2 has several simplifying assumptions
about the vasculature and tissue heterogeneity [1], and the
DCS and DOT measurements utilized different measure-
ment geometries. In the future, it would be interesting to
include measurement of Myc, a glycolysis marker, which
would enable further exploration of the relationship be-
tween cancer metabolism and proliferation [69].
Finally, we note that in the rKi67/DOT correlation
study, all of the samples with Ki67 expression in normal
tissues were obtained from premenopausal patients.
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all subjects used for the rKi67/DOT correlation could
have contributed to the correlations observed. Greater
proliferation in normal or benign tissues has been ob-
served in premenopausal women [70]. Ultimately, when
more tissues become available, we will be able to ascer-
tain the importance of menopausal status.
CD34-stained vascular properties were also compared
to DOT parameters. CD34 is expressed in the endothelial
cells of micro-vessels that migrate during angiogenesis
[33, 71, 72], and CD34 was used to assess vascularity in
the tumor samples. In the samples studied, only tumor
areas were studied so that only tumor vascularity was
assessed. Distant normal tissue was not available for inves-
tigation of the patient biopsies. We chose CD34 instead of
CD31, because a prior investigation [72] compared various
monoclonal antibodies for angiogenesis assessment and
found that the antibody to CD34 was more reliable than
the CD31 antibody. Among compared vascular parame-
ters, MVA in cancer tissues was correlated with rTHC,
rHbO2 and rμs'. These results met our expectation that
DOT measures increased blood supply to cancer through
the abnormally dilated blood vessels in cancer tissues [73].
The DOT tumor-to-normal tissue parameters have
previously been shown by Choe and co-workers [6] to
exhibit excellent differentiation between benign and ma-
lignant lesions. However, the association between DOT
parameters and tumor pathology was not explored.
Here, the use of tumor-to-normal ratios for both optical
and histological data minimized the effects of inter-
subject absolute property variation. Optical measure-
ment of total hemoglobin concentration has been
compared with histologically evaluated vascular proper-
ties in other studies. In a study by Srinivasan et al. using
near-infrared tomography, a correlation value of 0.3 was
obtained (p-value not reported) for association between
total hemoglobin concentration and the vessel density in
12 subjects, including both benign and malignant tu-
mors [38]. Zhu et al. measured total hemoglobin con-
centration using a combined system of ultrasound and
near infrared optical imaging, observing correlation be-
tween total hemoglobin concentration and micro-vessel
density (MVD, R = 0.64, p-value <0.05, 10 samples from
6 subjects) [39]. In a study of neoadjuvant chemotherapy
responders, Pakalniskis and colleagues observed signifi-
cant correlation between CD105-stained MVD and total
hemoglobin concentration in subjects with complete
pathological response, but not in those with partial
pathological response (p <0.001, n = 7, correlation coef-
ficient not reported) [37]. In our study, vessel area was
more strongly correlated (Spearman correlation coefficient
of 0.67, p-value 0.002, n = 19) with total hemoglobin con-
centration than the MVD, which was not significantly cor-
related with total hemoglobin concentration. We note thatgenerally the various studies reported in the literature differ
in the antibodies employed, the analysis methods utilized
(automatic vessel detection versus manual hotspot count-
ing), and, in some cases, in the way parameters are defined.
For example, in our work, MVD was defined as the number
of vessels per unit area (μm2), but in the work of Pakalniskis
et al., MVD is defined as a percentage of the combined
areas of CD105-stained vessels per total area of the slide.
Nuclear morphology has been shown to exhibit a more
elongated shape in cancer cells than normal cells [34–36].
Hajihashemi et al. observed higher μs' and more elong-
ation in cancer nuclei than the normal or benign tissues
[34, 35]. In our study, the tumor-to-normal ratio of nu-
clear compactness was smaller than 1, which indicates
that the tumor had more elongated nuclei than the nor-
mal tissues. The relative and cancer nuclear compactness
was only weakly correlated with rHbO2 and rStO2, re-
spectively, suggesting that in a less oxygenated environ-
ment, the nuclei tend to be more elongated.
Looking forward, tissue samples from normal breast tis-
sue need to be collected. The correlation between rTHC
and the CD34-stained MVA could be augmented and im-
proved, for example, if normal vessels were available. Al-
though our statistical power to detect clinically relevant
associations is limited by the number of samples available
for analysis, the cohort we have investigated has yielded
some potentially important findings. Further studies will
be needed to confirm the results reported here. In future
studies, tissues sent out for the trial, the Investigation of
Serial studies to Predict Your therapeutic response with
imaging and molecular analysis (I-SPY, American College
of Radiology and Imaging Network Protocol 6657), will be
also included. Finally, it is noteworthy that inclusion of
multiple ROI in each specimen produced stronger correl-
ation by partially accounting for cancer heterogeneity.
Conclusion
This pilot study has shown that DOT-measured and
DCS-measured breast cancer physiological parameters
are correlated with proliferation of cancer cells and with
formation of abnormally dilated blood vessels in cancer.
The results suggest that DOT may be useful as a non-
invasive assessment tool for specific cancer biomarkers,
especially for cancer proliferation. As Ki67 is a well-
known prognostic index and an early predictor of tumor
response to chemotherapy, the high correlation between
Ki67 and DOT-measured tissue oxygenation further sug-
gests the potential of optical imaging and monitoring.
The optical methods utilize non-ionizing radiation and
can be easily employed at the bedside. These features,
coupled with predictive capability, are particularly at-
tractive for patients who need frequent monitoring, for
example, during chemotherapy, and for women with radio-
graphically dense breast tissue.
Chung et al. Breast Cancer Research  (2015) 17:72 Page 12 of 14Additional file
Additional file 1: Table S1. Subjects for the correlation studies between
diffuse optical tomography (DOT) parameters versus various cancer
biomarkers. Table S2. Cancer and normal Ki67 values used for the
calculation of tumor-to-normal ratio of Ki67. Table S3. Correlation between
cancer Ki67 percent versus DOT-relative parameters. Table S4. Range of
values of the biomarkers used for the correlation studies. Table S5. DOT
parameters for the Ki67-positive and Ki67-negative cancer groups. Table S6.
Correlation of relative nuclear compactness versus DOT parameters.
Table S7. Correlation of cancer nuclear compactness versus DOT parameters.
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